Nanoemulsion-based adjuvant increases immunity and cross protection against influenza

Sep 9 2009

NanoBio Corp. announced today that data from a large ferret study indicates that its intranasal, nanoemulsion-based adjuvant elicits robust immunity and cross protection against influenza using 1/15^th of the standard antigen dose, without evidence of toxicity or tolerability concerns. The company also announced that data from a large GLP toxicity study in rabbits demonstrated similarly robust immune responses without signs of toxicity or inflammation.

Data from both studies will be presented on Sunday, September 13^th at 11:15 am at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) at the Moscone Center, San Francisco, CA. The poster references are as follows:

Poster # G1-877: Intranasal W₈₀5EC Adjuvanted Fluzone Provides Robust Immunity and Cross-Protection in Ferrets

Poster # G1-878: A GLP Toxicity and Immunogenicity Study of NB-1008, an Intranasal W₈₀5EC-Adjuvanted-Fluzone Vaccine

NanoBio will sponsor corporate booth # 1711 at ICAAC, where information on the company’s development programs for its vaccine, dermatological and anti-infective programs will be available.

http://www.nanobio.com/